Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Trial Profile

Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Cytarabine; Etoposide; Lintuzumab; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top